DOCSLIB.ORG

View Numinus' Briefing Note to Health Canada Here

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View Numinus' Briefing Note to Health Canada Here November 20, 2020 Patty Hajdu Honourable Minister of Health Health Canada Email: [email protected] Dear Minister Hajdu, On behalf of the Numinus Wellness Clinical Advisory Board*, please find enclosed a briefing note and appendices making recommendations for the revision of Health Canada’s Special Access Programme. We would appreciate the opportunity to have a follow up call with relevant Health Canada staff to review these recommendations if this would be of assistance. Sincerely, ____________________________ ____________________________ Evan Wood, MD, PhD, FRCPC Devon Christie, MD, CCFP, RTC Chief Medical Officer Medical Director *Gabor Maté, M.D.,C.M, Author & Retired Physician, Pam Kryskow, M.D., CCFP, Physician & Clinical Instructor, UBC, Zach Walsh, PhD, Professor, Psychology, UBC, Kate Browning RN, Administrator & Instructor, Holistic Health, Langara College, Dr. Jason Marr, BScH, COC, ND, Founder & Director of Evoke Integrative Medicine Ltd. cc: Pierre Sabourin, Assistant Deputy Minister Health Products and Food Branch, Health Canada Email: [email protected] Eric Costen, Associate Assistant Deputy Minister Controlled Substances and Cannabis Branch, Health Canada Email: [email protected] numinus.ca [email protected] TITLE: Revising Health Canada’s Special Access Program to Allow Pre-Approval Access to MDMA and Psilocybin PREPARED FOR: Patty Hajdu, Honourable Minister of Health DATE: November 20, 2020 ISSUE: There is a large and growing burden of mental illness affecting Canadians. In some cases, this is severe and can be life threatening for a range of reasons (e.g. opioid overdose, suicide). Existing treatments for severe mental illness are often ineffective and associated with unwanted side effects meaning new treatment modalities are urgently needed. A substantial body of research, including the completion of a growing number of randomized clinical trials, has demonstrated that psychedelic-assisted psychotherapy using psilocybin, MDMA and other substances is emerging as a novel approach for the treatment of a host of mental illnesses including treatment-resistant depression, post-traumatic stress disorder, substance-use disorder, and severe anxiety associated with a terminal diagnosis (see Appendix 2). These treatment modalities remain under investigation and are presently illegal in Canada, which presents a serious ethical concern, given that although phase III clinical trials are ongoing, including in Canada, patients who may benefit from pre-approval access through Health Canada’s Special Access Programme are precluded from doing so as a result of current regulatory restrictions. This includes patients who have volunteered for, and graduated from, clinical trials in Canada and who may benefit from further treatment - and is not dissimilar to a volunteer to a cancer chemotherapy trial being unable to access ongoing investigational medication despite apparent clinical benefit once the trial is completed. BACKGROUND: Historically, pre-approval access for medications in the drug development pipeline was possible through Canada’s Special Access Programme. As summarized in a 2013 Canada Gazette (Vol. 147, No 22, October 2013), however, “The Government is concerned that the Special Access Programme (SAP) could be used to give individuals access to heroin, unauthorized products containing cocaine (benzoylmethylecgonine) and “restricted drugs” (defined in Part J of the FDR). Accordingly, amendments to the FDR and the Narcotic Control Regulations (NCR), with consequential amendments to the New Classes of Practitioners Regulations (NCPR), are needed to prevent access to these substances through the programme.” While government regulations have been revised to enable legal access to heroin for medical purposes, access to psychedelic medications through the SAP remains not possible. Importantly, the psychedelic substances being considered in research trials were unrelated to the focus on diacetylmorphine (heroin) which was the rationale for the change in 2013 whereas the removal of psychedelic medicines from the Special Access Programme could be viewed as totally unrelated (and inappropriate given existing research). Specifically, when the change to the Special Access Programme was made in 2013, decades of clinical research into psychedelic substances had been completed and there were already a large number of clinical trials demonstrating the safety and likely benefits of psychedelic-assisted psychotherapy (Appendix 2). Additionally, in certain Indigenous cultures (e.g. Mazatec people of Mexico), psychedelic substances, such as psilocybin mushrooms, have been used in traditional medicine contexts for centuries and used recreationally without documented concerns (1). Lastly, there is growing recognition of stigma and racial discrimination as underpinning drug policies in North America (i.e. laws not based on clinical or public health evidence) and revisiting access to psychedelic assisted psychotherapy is therefore timely. Since the above mental health conditions are often life threatening and existing treatments have major limitations in terms of success rates and side effects, Canadian citizens suffering with these conditions and who have exhausted conventional treatments would benefit from strategies that enable access to psychedelic-assisted psychotherapy prior to full approval by Health Canada while these drugs remain in clinical trials. Recent approval of Section-56 exemptions for Canadians suffering with anxiety associated with terminal diagnoses to lawfully access psilocybin represents a positive step forward for Canadians who wish to access potentially life saving therapy; however, Section-56 exemptions do not account for two very important considerations regarding safety: 1. Access to a safe supply of psilocybin (including natural sources) that does not involve obtaining the drug from the unregulated illicit market 2. Parameters delineating the context in which the drug will be administered, which is critical for psychedelic substances due to drug interactions and other concerns (Appendix 1) In the above context, clinical scientists have developed a knowledge base and best practices regarding methodologies for safe and effective delivery of psychedelic-assisted psychotherapy. Importantly, psychedelic-assisted psychotherapy is distinct in many ways and requires special attention to the context of delivery for safety and efficacy. Specifically, psychedelic medicines can not be considered in the same way as many pharmaceutical drugs, since effective treatment combines the psychedelic drug experience with a carefully established psychotherapeutic protocol involving: 1. Qualified mental health providers 2. Screening parameters for appropriate candidates for treatment including ensuring patients are not using other substances including medications that may lead to negative drug interactions 3. Psychological preparation sessions prior to psychedelic-assisted psychotherapy 4. Special considerations for the psychedelic-assisted session including the physical setting while under the influence of the medication 5. Psychological integration sessions and follow up in the weeks following the psychedelic- assisted psychotherapy session 6. Often, consideration for multiple psychedelic sessions (e.g. a month apart) as research (see appendix 3) has demonstrated that repeated sessions are often more effective than single sessions Currently, the two drugs in development that show promise when combined with psychotherapy for the aforementioned mental health conditions are psilocybin and MDMA, both of which are restricted under the Food and Drug Act Schedule J and therefore may not be accessed through the Special Access Programme. Given that both MDMA and psilocybin are already currently being developed for clinical trials, and are therefore accessible, and that there is a high burden of illness affecting Canadians for the aforementioned conditions, the Special Access Programme represents the most appropriate route for access that would ensure safe supply of the drug and, with additional parameters being set (Appendix 1), to appropriate clinical settings where the drug- assisted psychotherapy protocols could safely take place. RECOMMENDATION: We recommend that the Health Canada Special Access Programme be revised so as to allow for consideration of applications for access to MDMA- and psilocybin- assisted psychotherapies via the Special Access Programme mechanism. We also recommend that the Special Access Programme further develop a process for approving SAP requests that considers the following elements to ensure safety: - Description of how the medication will be obtained (allowing for both synthetic and natural forms of psilocybin given Indigenous traditional practices) and safely stored prior to clinical use - Description of the psychotherapy modality (e.g. motivational enhancement), including a brief description of the preparatory psychotherapy and post psychedelic psychotherapy integration, as well as the necessary training and credentials of who will be providing the psychotherapy - Description of an appropriate location where the psychedelic-assisted psychotherapy will be safely provided with consideration given to ensuring patient safety while under the influence of the medication A draft proposed Special Access Programme considerations template (Appendix 1), a summary of published literature (Appendix 2), and PDFs of relevant literature (Appendix 3) are attached for your interest. Given the known
Load more

Recommended publications
  • Ormond Beach Daytona Beach Holly Hill Your Own
    GROW INSIDE ORMOND BEACH DAYTONA BEACH HOLLY HILL YOUR OWN In Garden Nook: Orchids not that hard Page A13 Vol. 6, No. 31 Your Local News and Information Source • www.HometownNewsOL.com Friday, Aug. 26, 2011 Community New state laws mean less You can earn money from home talking about what you already know! If you feel like you Notes are an expert on anything, sign up start earning money as a FREE oversight for local development Broadcaster!and Dance clinic planned • STREAM & SELL YOUR VIDEOS • STREAM AND SELL YOUR LIVE EVENTS By John Bozzo Mr. Goss said this will mean less is what local govern- • VIDEOS ON DEMAND ENCORE Baton & Dance For Hometown News paperwork but more responsibility ments use to regu- studio in Holly Hill will hold Also Offering Videos on Demand for local officials, who are still sort- late land use within Sell your event or educational videos online. a free show and clinic from ORMOND BEACH — With slides ing out what the new law means their cities. They 9:30 a.m. to noon, Saturday, projected on a screen in a small and how decisions in one commu- are used to plan for Aug. 27. No experience is room, the City Commission recent- nity will impact a neighboring the needs of the SIGN UP FOR FREE! necessary. ly studied what responsibilities a community. communities and WWW.HDBroadcasters.COM For more information new state law on growth and urban While many believe the relax- to protect natural about this free clinic, call planning will place in their hands.
    [Show full text]
  • Download Book Sacred Journeys As
    Sa cred Jour neys: ©2015, 2016, 2017 Artscience Im ages: authors and friends, com pany and press pic- tures, PhotoDisc, Corel, Wikipedia, Mindlift Beeldbankiers. Dis tri bu tion: Boekencoöperatie Nederland u.a. email: [email protected] www.boekcoop.nl www.boekenroute.nl (webshop) All rights re served, in clud ing dig i tal re dis tri bu tion and ebook First editiion: De cem ber 2015, Sec ond, ap pended edition April 2016 Third edition Jan. 2017 ISBN 9789492079091 pub lisher: Onderstroomboven Collectief im print: Artscience. Pa perback price € 6,95 Con tents 1 Pre fa ce 7 2 Tripping: the process 10 Journey to the dream 10 The pre pa ra ti on 11 Pha ses, gig gling 13 Iso la ti on, li mi na li ty, the dark 14 Peak 19 Sit ters: de sig na ted hel pers 22 The mys ti cal, re gres si on 26 Rebirth and de ath 27 The end of the trip: co ming down 28 Over sti mu la ti on 29 The af ter-ef fects 30 3 Set and Set ting 32 Agen da 33 Pla ce 34 With whom, with what? 34 Bon ding and trans fe ren ce 35 Dif fe rent ways of using 36 4 Pur po se 37 Dee per goals 38 Over co ming fear 40 To le ran ce 41 5 Ri tu als and Group ses sions 42 He a ling jour neys, mys ti cal in sights 44 Me di cal use 45 Re pe ti ti on, loops 46 Stages of a ritu al 49 Ri tes of pas sa ge: ini ti a ti on 50 Contact – alignment - group mind 52 Struc tu re amidst cha os 54 To copy an existing ritu al or to crea te somet hing new 54 6 Sanc tu a ry, safe spa ce 57 Sa fe ty first 57 Sa cred spa ce, tem po ra ry au to no mous zone 58 Hol ding spa ce and cir cle in te gri ty 61 7 His to ry
    [Show full text]
  • Microdosing Psychedelics: Results from the Global Drug Survey 2019
    Microdosing Psychedelics: Results from the Global Drug Survey 2019 Petranker, R.1,2, Anderson, T.2,3, Maier, L. J.4,5, Barratt, M. J.6,7, Ferris, J. A.8, & Winstock, A. R.9,10 1 Clinical Psychology, York University, Toronto, ON, Canada 2 Psychedelic Studies Research Program, University of Toronto Mississauga, Mississauga, ON, Canada 3 Department of Psychology, University of Toronto, Toronto, ON, Canada. 4 Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, CA, United States 5 Early Postdoc Mobility Grantee, Swiss National Science Foundation, Bern, Switzerland 6 Social and Global Studies Centre, RMIT University, Australia 7 National Drug and Alcohol Research Centre, UNSW Sydney, Australia 8 Centre for Health Services Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia 9 University College London, Gower St, Bloomsbury, London, UK 10 Global Drug Survey Ltd, London, UK *Corresponding Author Rotem Petranker Toronto, ON, Canada Email: [email protected] Abstract Microdosing psychedelics – the practice of taking small, sub-hallucinogenic amounts of substances like psilocybin-containing mushrooms or LSD – is becoming increasingly popular. Despite its surging popularity, little is known about the effects of this practice. This research had two aims. First, we attempted to replicate previous findings in the literature regarding the subjective benefits and challenges involved in microdosing. Second, we wanted to examine whether people who microdose test their substances for purity before consumption, and whether approach-intention to microdosing was predictive of more reported benefits. 7,313 people who reported microdosing, from a variety of countries, ages, and other demographics participated in our survey.
    [Show full text]
  • Community and Practice in Two Generations of Online Illicit Drugs Discussions
    Community and practice in two generations of online illicit drugs discussions A thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Humanities. 2020 P. O. Enghoff School of Social Sciences, Department of Criminology and Criminal Justice Table of Contents Abstract .................................................................................................................. 5 Acknowledgements .............................................................................................. 8 Other acknowledgements .................................................................................... 9 The author .............................................................................................................. 9 Chapter 1. Introduction ..................................................................................... 10 1.1 Background ........................................................................................... 11 1.2 Summary of thesis contents ................................................................ 19 1.2.1 Literature review .......................................................................... 20 1.2.2 Research design ............................................................................. 24 1.2.3 Research papers ............................................................................ 28 1.2.4 Discussion ...................................................................................... 31 Chapter 2. Literature review ............................................................................
    [Show full text]
  • BC2019-Printproginccovers-High.Pdf
    CONTENTS Welcome with Acknowledgements 1 Talk Abstracts (Alphabetically by Presenter) 3 Programme (Friday) 32–36 Programme (Saturday) 37–41 Programme (Sunday) 42–46 Installations 47–52 Film Festival 53–59 Entertainment 67–68 Workshops 69–77 Visionary Art 78 Invited Speaker & Committee Biographies 79–91 University Map 93 Area Map 94 King William Court – Ground Floor Map 95 King William Court – Third Floor Map 96 Dreadnought Building Map (Telesterion, Underworld, Etc.) 97 The Team 99 Safer Spaces Policy 101 General Information 107 BREAK TIMES - ALL DAYS 11:00 – 11:30 Break 13:00 – 14:30 Lunch 16:30 – 17:00 Break WELCOME & ACKNOWLEDGEMENTS WELCOME & ACKNOWLEDGEMENTS for curating the visionary art exhibition, you bring that extra special element to BC. Ashleigh Murphy-Beiner & Ali Beiner for your hard work, in your already busy lives, as our sponsorship team, which gives us more financial freedom to put on such a unique event. Paul Callahan for curating the Psychedelic Cinema, a fantastic line up this year, and thanks to Sam Oliver for stepping in last minute to help with this, great work! Andy Millns for stepping up in programming our installations, thank you! Darren Springer for your contribution to the academic programme, your perspective always brings new light. Andy Roberts for your help with merchandising, and your enlightening presence. Julian Vayne, another enlightening and uplifting presence, thank you for your contribution! To Rob Dickins for producing the 8 circuit booklet for the welcome packs, and organising the book stall, your expertise is always valuable. To Maria Papaspyrou for bringing the sacred feminine and TRIPPth.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Nove Psihoaktivne Tvari
    TRENUTNO AKTIVNI SMART SHOPOVI U RH SINTETSKI KANABINOIDI TRIPTAMINI TOBACOO I VIDEOTEKA - ČAKOVEC Tvari koji oponašaju učinke kanabisa. Tvari koje izazivaju halucinogeno djelovanje. ■■Ulica kralja Tomislava 4 Vežu se na kanabinoidne receptore CB1 i CB2. SEKS SHOP I SMART SHOP - KOPRIVNICA ■■Ivana Generalić 3 HEAD SHOP SHOP - OSIJEK ■■Strossmayerova 39 SMART SHOP ART-MUSIK - PULA z primjeri kemijskih naziva: 5-MeO-DMT, 5-MeO-AMT, DPT ■■Zadarska 3 ■ IGROW SHOP - RIJEKA ■ izazivaju halucinogeno djelovanje; ■■Blaža Polića 5 najčešće se konzumiraju pušenjem, oralno, ušmrkavanjem, inhalacijom, injektiranjem SMART SHOP” - SLAVONSKI BROD ■■mijenjaju doživljaj realnosti, uzrokuju strah, ■■Starčevića 23 tjeskobu, povećanje srčanog pulsa IGROW SHOP - SPLIT ■■Mihovilova širina 19 z primjeri kemijskih naziva: JWH-018, NOVE JWH-250, JWH-122, AM-2201, RCS-04, SMART SHOP - ŠIBENIK DRUGI ■■Zagrebačka 9 UR-144, 5F UR-144, 5Cl UR-144 PSIHOAKTIVNE SNAIL SMART SHOP - ZADAR Tvari koje ne pripadaju niti jednoj od ■■mješavina bilja koja se reklamira kao “egzotični ■■Stomorica 2 navedenih skupina. Pojavljuju se u obliku mirisi” ili osvježivači prostora uz čestu TVARI SMART SHOP - ZAGREB napomenu kako nisu za konzumaciju tableta, praha, biljnih pripravaka te ■ ■ Maradona smart shop Tkalčićeva 12 ■■sadrže sintetske kanabinoide pa se uzrokuju različite psihoaktivne učinke. ■Grow shopzg Ilica 93 ■ pušenjem postižu učinci slični kanabisu ■■King size head shop Petrinjska 4 ■ ■■Smart shop Apoteka Selska 215 ■ imaju psihoaktivni učinak sličan učinku ■■Nail grow shop
    [Show full text]
  • Psychedelic Gospels
    The Psychedelic Gospels The Psychedelic Gospels The Secret History of Hallucinogens in Christianity Jerry B. Brown, Ph.D., and Julie M. Brown, M.A. Park Street Press Rochester, Vermont • Toronto, Canada Park Street Press One Park Street Rochester, Vermont 05767 www.ParkStPress.com Park Street Press is a division of Inner Traditions International Copyright © 2016 by Jerry B. Brown and Julie M. Brown All rights reserved. No part of this book may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the publisher. Note to the Reader: The information provided in this book is for educational, historical, and cultural interest only and should not be construed in any way as advocacy for the use of hallucinogens. Neither the authors nor the publishers assume any responsibility for physical, psychological, legal, or any other consequences arising from these substances. Library of Congress Cataloging-in-Publication Data [cip to come] Printed and bound in XXXXX 10 9 8 7 6 5 4 3 2 1 Text design and layout by Priscilla Baker This book was typeset in Garamond Premier Pro with Albertus and Myriad Pro used as display typefaces All Bible quotations are from the King James Bible Online. A portion of proceeds from the sale of this book will support the Multidisciplinary Association for Psychedelic Studies (MAPS). Founded in 1986, MAPS is a 501(c)(3) nonprofit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.
    [Show full text]
  • 5-Country RAR Report Lenka Vavrincikova, Hana Fidesova, Barbara Janikova & Jean-Paul Grund
    New Psychoactive Substances among People Who Use Drugs Heavily. Towards Effective and Comprehensive Health Responses in Europe. 5-country RAR report Lenka Vavrincikova, Hana Fidesova, Barbara Janikova & Jean-Paul Grund New Psychoactive Substances among People Who Use Drugs Heavily. Towards Effective and Comprehensive Health Responses in Europe. Department of Addictology First Faculty of Medicine Charles University in Prague General University Hospital in Prague Czech Republic February 2016 JUST/2013/DPIP 4000004774 (1/3/2014 to 28/2/2016) Disclaimer "This publication has been produced with the financial support of the Drug Prevention and Information Programme of the European Union. The contents of this publication are the sole responsibility of the implementing partners: Agência Piaget Para o Desenvolvimento – APDES (Portugal), Charles University in Prague – CUNI (Czech Republic), De Regenboog Groep (RG) (The Netherlands), Carusel Association (Romania), Programs of Development, Social Support and Medical Cooperation – PRAKSIS (Greece), SANANIM (Czech Republic), and MONAR – Association, Outpatients Clinic in Krakow (Poland), and can in no way be taken to reflect the views of the European Commission." New Psychoactive Substances among People Who Use Drugs Heavily. Towards Effective and Comprehensive Health Responses in Europe. 5-country RAR report Lenka Vavrincikova, Hana Fidesova, Barbara Janikova & Jean-Paul Grund Acknowledgements Financial support for this study was provided by the Drug Prevention and Information Program of the European
    [Show full text]
  • Do Drugs Have Religious Import?
    A-. ,'Smith,:L: H., Jesse, R., Grob, C., Agar, A., Walsh, R. The Oral History of Psychedelics ~esearch $project, \I: Do drugs . -- - - - x - - i:~svcholoev.44 (2), 120- 140,2003. Huston Smith ef al. 121 ... ~ .~ .. ~ - . -- .- .. .. ,- . - . .. ROBERT JESSE serves as the p~sidentof the Coun- DO DRUGS HAVE RELIGIOUS IMPORT? cil on Spiritual Practices, a collaboration among spir- A 40-YEAR RETROSPECTIVE itualguides,experta in the behavioral and biomedical sdences,andscholars ofreligion. CSPsponsors scien- tific research and encourages dialogue about J. approaches to primary religious experience and con- HUSMN SMITH is the Thomas Watson Professor ditions that helpchannel such experiences into favor- of Religion and Distinguished Adjunct Professor of able long-term outcomes. He led the drafting of CSPs Code of Ethics for Philosophy, Emeritus, Syracuse University. For 15 Spiritual Guides, intended to foster wholesomeness in practices intended years, he was a professor of philosophy at M.I.T., and or likely to be transfornative. An engineer by training, he formerly for a decade before that he taught at Washington Uni- worked in software development. versity in St. Louis. hlost recently, he has aerved as a visiting professor of religious studies, University of Califomia, Berkeley. Holder of 12 honorary degrees, GARY BRAVO graduated from Harvard University his 14 books include The World's Religio~,which has with a degree in biology and did his medical and psy- sold more than 2 ?4 million copies, and Why Religion chiatric training at the University of California, bfatfers, which won the Wilbur Award for the best book on religion pub Irvine, College of hledicine.
    [Show full text]
  • Dosing Creativity
    UvA-DARE (Digital Academic Repository) Drug-craft On the configurations of psychedelic efficacies Mishra, S. Publication date 2020 Document Version Other version License Other Link to publication Citation for published version (APA): Mishra, S. (2020). Drug-craft: On the configurations of psychedelic efficacies. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:06 Oct 2021 Chapter 1 Dosing Creativity Besides alcohol, I don’t really use drugs and have little interest in them, but this microdosing – for work, being creative, for being focused and effective… its increased use by Silicon Valley professionals – it did catch my attention. You research drugs, what do you think about it? I would like to try it someday. (Informal conversation, Amsterdam 2017) This is what Jan said to me, on an afternoon at my research institute in Amsterdam, as we bumped into each other by the department’s coffee machine.
    [Show full text]
  • The Effect of Microdosing Classical Psychedelics on Cognitive Performance
    University of Central Florida STARS Honors Undergraduate Theses UCF Theses and Dissertations 2021 The Effect of Microdosing Classical Psychedelics On Cognitive Performance Michael Harris University of Central Florida Part of the Chemicals and Drugs Commons, and the Psychology Commons Find similar works at: https://stars.library.ucf.edu/honorstheses University of Central Florida Libraries http://library.ucf.edu This Open Access is brought to you for free and open access by the UCF Theses and Dissertations at STARS. It has been accepted for inclusion in Honors Undergraduate Theses by an authorized administrator of STARS. For more information, please contact [email protected]. Recommended Citation Harris, Michael, "The Effect of Microdosing Classical Psychedelics On Cognitive Performance" (2021). Honors Undergraduate Theses. 974. https://stars.library.ucf.edu/honorstheses/974 THE EFFECT OF MICRODOSING CLASSICAL PSYCHEDELICS ON COGNITIVE PERFORMANCE by MICHAEL HARRIS A thesis submitted in partial fulfillment of the requirements for the Honors in the Major Program in Psychology in the College of Sciences and in the Burnett Honors College at the University of Central Florida Orlando, Florida Spring Term, 2021 Thesis Chair: Daniel McConnell, PhD ABSTRACT Public interest and scientific inquiry are currently bringing psychedelic research back into the spotlight after a decades-long respite from clinical human trials. A majority of the research during this recent renaissance has surrounded applications of psychedelics in the fields of mental health. Less attention is being focused to other research areas where psychedelics may also prove informative, such as cognition and information processing. A common trend taking place is the act of administering very small doses of psychedelics as a potential cognitive enhancer, called microdosing.
    [Show full text]